A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary

Author： Assersohn L.   Norman A.R.   Cunningham D.   Iveson T.   Seymour M.   Hickish T.   Massey A.   Prior Y.   Hill M.E.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.39, Iss.8, 2003-05, pp. : 1121-1128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-Fluorouracil (5-FU) Continuous Intravenous Infusion Compared with Bolus Administration. Final Results of a Randomised Trial in Metastatic Colorectal Cancer

By Rougier P.   Paillot B.   LaPlanche A.   Morvan F.   Seitz J.F.   Rekacewicz C.   Laplaige P.   Jacob J.   Grandjouan S.   Tigaud J.M.   Fabri M.C.   Luboinski M.   Ducreux M.  

European Journal of Cancer, Vol. 33, Iss. 11, 1997-10 ,pp. : 1789-1793

Elsevier

Access to resources Recommend Favorite

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer - a phase II study.

By Allen M.   Vaughan M.   Webb A.   Johnston S.   Savage P.   Eisen T.   Bates S.   Morre J.   Ahern R.   Gore M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 83-83

Elsevier

Access to resources Recommend Favorite

Plasma and Salivary Pharmacokinetics of 5-Fluorouracil (5-FU) in Patients with Metastatic Colorectal Cancer Receiving 5-FU Bolus Plus Continuous Infusion with High-dose Folinic Acid

By Joulia J.M.   Pinguet F.   Ychou M.   Duffour J.   Astre C.   Bressolle F.  

European Journal of Cancer, Vol. 35, Iss. 2, 1999-02 ,pp. : 296-301

Elsevier

Access to resources Recommend Favorite

Bolus injection (2-4min) versus short-term (10-20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial

By Glimelius B.   Jakobsen A.   Graf W.   Berglund A.   Gadeberg C.   Hansen P.   Kjaer M.   Brunsgaard N.   Sandberg E.   Lindberg B.   Sellstrom H.   Lorentz T.   Pahlman L.   Gustavsson B.  

European Journal of Cancer, Vol. 34, Iss. 5, 1998-04 ,pp. : 674-678

Elsevier

Access to resources Recommend Favorite

FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results

By Pacini P.   Rinaldini M.   Algeri R.   Guarneri A.   Tucci E.   Barsanti G.   Neri B.   Bastiani P.   Marzano S.   Fallai C.  

European Journal of Cancer, Vol. 36, Iss. 8, 2000-05 ,pp. : 966-975

Elsevier

Access to resources Recommend Favorite